Compare DMO & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMO | CDXS |
|---|---|---|
| Founded | 2009 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.8M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | DMO | CDXS |
|---|---|---|
| Price | $11.56 | $1.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.6K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 12.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,932,000.00 |
| Revenue This Year | N/A | $12.88 |
| Revenue Next Year | N/A | $21.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.00 | $1.52 |
| 52 Week High | $11.80 | $6.08 |
| Indicator | DMO | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 36.13 |
| Support Level | $11.75 | $1.52 |
| Resistance Level | $11.68 | $1.79 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 2.11 | 26.53 |
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.